LG Chem 
Welcome,         Profile    Billing    Logout  
 38 Products   109 Diseases   38 Products   35 Trials   1866 News 


«12...678910111213141516...1819»
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
    Trial completion date, Trial primary completion date, Metastases:  Tivozanib + Enzalutamide in Adv Prostate Cancer (clinicaltrials.gov) -  Sep 1, 2020   
    P2,  N=5, Active, not recruiting, 
    Completed --> Terminated; Lack of new studies contributing subjects to this study Trial completion date: Jun 2020 --> Jun 2023 | Trial primary completion date: Dec 2019 --> Dec 2022
  • ||||||||||  CUE-101 / Cue Biopharma, LG Chem
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Aug 24, 2020   
    P1,  N=85, Recruiting, 
    Trial completion date: Jun 2020 --> Jun 2023 | Trial primary completion date: Dec 2019 --> Dec 2022 N=50 --> 85 | Trial completion date: Nov 2022 --> Aug 2023 | Trial primary completion date: Jun 2021 --> Jul 2022
  • ||||||||||  Follitrope (recombinant human follicle stimulating hormone) / LG Chem
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Observational Study to Develop Dosing Chart (clinicaltrials.gov) -  Aug 7, 2020   
    P=N/A,  N=534, Completed, 
    Available data do not support the hypothesis of an association of DPP4i treatment with malignancies, with a possible beneficial effect for colon-rectal cancer. Recruiting --> Completed | N=1000 --> 534 | Trial completion date: Nov 2020 --> Jul 2020 | Trial primary completion date: Nov 2020 --> Jul 2020
  • ||||||||||  Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
    Trial completion, Trial completion date, Trial primary completion date:  GLITTER 1: Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (clinicaltrials.gov) -  Jul 9, 2020   
    P3,  N=550, Completed, 
    Recruiting --> Completed | N=1000 --> 534 | Trial completion date: Nov 2020 --> Jul 2020 | Trial primary completion date: Nov 2020 --> Jul 2020 Active, not recruiting --> Completed | Trial completion date: Feb 2020 --> Aug 2019 | Trial primary completion date: Feb 2020 --> Aug 2019
  • ||||||||||  Gemiglo (gemigliptin) / Sanofi, LG Chem
    Journal:  Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome. (Pubmed Central) -  Jun 26, 2020   
    Our study showed that tivozanib as third-line or fourth-line therapy improved progression-free survival and was better tolerated compared with sorafenib in patients with metastatic renal cell carcinoma. The present study shows that activation of the NLRP3 inflammasome contributes to UUO-induced renal fibrosis and the renoprotective effect of gemigliptin is associated with attenuation of NLRP3 inflammasome activation.
  • ||||||||||  tigulixostat (LC350189) / LG Chem
    Trial completion, Trial completion date:  The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults (clinicaltrials.gov) -  Jun 25, 2020   
    P1,  N=24, Completed, 
    The present study shows that activation of the NLRP3 inflammasome contributes to UUO-induced renal fibrosis and the renoprotective effect of gemigliptin is associated with attenuation of NLRP3 inflammasome activation. Not yet recruiting --> Completed | Trial completion date: May 2020 --> Feb 2020
  • ||||||||||  tigulixostat (LC350189) / LG Chem
    Trial completion:  Mass Balance Study of [14C]LC350189 in Healthy Volunteers (clinicaltrials.gov) -  Jun 25, 2020   
    P1,  N=6, Completed, 
    Not yet recruiting --> Completed | Trial completion date: May 2020 --> Feb 2020 Not yet recruiting --> Completed
  • ||||||||||  ficlatuzumab (AV-299) / AVEO, Biodesix, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    P1 data, Journal:  Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. (Pubmed Central) -  Jun 19, 2020   
    An increase in peripheral T cells, particularly the CD8 subset, was associated with treatment response whereas progression was associated with expansion of a distinct myeloid population. This well-tolerated combination demonstrated promising activity in cetuximab-resistant, advanced HNSCC.
  • ||||||||||  Fotivda (tivozanib) / AVEO, Jazz
    Review, Journal:  Tivozanib in renal cell carcinoma: a new approach to previously treated disease. (Pubmed Central) -  Jun 19, 2020   
    This review seeks to characterize tivozanib within the context of RCC by highlighting preclinical and early clinical trials alongside the phase III trials in RCC, TIVO-1, and TIVO-3. We also aim to explore further trials of tivozanib, whether in combination with other agents and/or in differing disease settings, while providing insight into the utility of tivozanib as a clinical tool for the management of RCC.
  • ||||||||||  Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
    Trial completion date, Combination therapy, Metastases:  TiNivo study : Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC (clinicaltrials.gov) -  Jun 4, 2020   
    P1/2,  N=28, Active, not recruiting, 
    We also aim to explore further trials of tivozanib, whether in combination with other agents and/or in differing disease settings, while providing insight into the utility of tivozanib as a clinical tool for the management of RCC. Trial completion date: Dec 2018 --> Dec 2020